Showing 4121-4130 of 7172 results for "".
- BTL Introduces EMFACE Technologyhttps://practicaldermatology.com/news/btl-introduces-emface-technology/2461033/Described as the result of many years of institutional knowledge of the simultaneous emission of radio frequency and electromagnetic energies, EMFACE™ is the newest innovation from BTL. It utilizes a patented technology of muscle contraction and skin tissue heating. &quo
- Avita Medical's Spray-On Skin Cells Demonstrate Proof of Concept in Aging Skin and EBhttps://practicaldermatology.com/news/avita-medicals-spray-on-skin-cells-demonstrate-proof-of-concept-in-rejuvenation-and-eb/2461028/Preclinical data successfully established proof of concept for Avita Medical’s Spray-On Skin Cells in skin rejuvenation and epidermolysis bullosa (EB), the company reports. AVITA Medical’s first US product, the RECELL System, was approved by FDA in September 2018.
- First Patient Enrolled in Phase 2b Study of Oral Orismilast in Psoriasishttps://practicaldermatology.com/news/first-patient-enrolled-in-phase-2b-study-of-oral-orismilast-in-psoriasis/2461024/The first patient has been enrolled in IASOS, a Phase 2b dose-ranging study evaluating the safety and efficacy of oral orismilast in patients with moderate to severe psoriasis, according to UNION therapeutics. Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory p
- Obagi Enters Device Arena with The Skintrinsiq Systemhttps://practicaldermatology.com/news/obagi-enters-device-arena-with-the-skintrinsiq-system/2461019/Obagi is launching the Skintrinsiq device, its first entry into the complementary skincare device market. The Skintrinsiq system extracts impurities then infuses Obagi skincare products via treatment protocols customized for individual skincare needs. "The uni
- Data Demonstrate Safety, Efficacy of Dupilumab for AD in Patients as Young as Six Monthshttps://practicaldermatology.com/news/data-demonstrate-safety-efficacy-of-dupilumab-for-ad-in-patients-as-young-as-six-months/2461005/Data demonstrating the safety and efficacy of Sanofi and Regeneron’s
- ASDSA Honorees Recognized for Engagement in Initiatives that Benefit Dermatologic Surgery and Patientshttps://practicaldermatology.com/news/asdsa-honorees-recognized-for-engagement-in-initiatives-that-benefit-dermatologic-surgery-and-patients/2460995/The American Society for Dermatologic Surgery Association (ASDSA) announced the recipients of its annual awards this week during the ASDS / ASDSA Virtual Annual Meeting. ASDSA is proud to recognize its members who contribute significant time and expertise advocating for patient safety,
- New International Recommendations for Treating Acne Scars with Energy-Based Deviceshttps://practicaldermatology.com/news/new-international-recommendations-for-treating-acne-scars-with-energy-based-devices/2460990/Energy-based devices are the first-line treatments for a variety of acne scars, according to new international consensus recommendations published in Lasers in Surgery and Medicine. For the first time
- New Collaboration Seeks to Establish Nocturnal Scratch as a Digital Endpoint for ADhttps://practicaldermatology.com/news/new-collaboration-seeks-to-establish-nocturnal-scratch-as-a-digital-endpoint-for-ad/2460986/Advancing the use of digital endpoints in medical research and care, a new collaboration between
- Better Together: Castle Biosciences’ Full DecisionDx Portfolio to Be Interfaced with ModMed’s EMAhttps://practicaldermatology.com/news/better-together-castle-biosciences-full-decisiondx-portfolio-to-be-interfaced-with-modmeds-ema/2460982/Castle Biosciences, Inc’s full DecisionDx portfolio of dermatologic tests will be interfaces with EMA, ModMed’s electronic health records system, by year-end 2021 The interface is designed to enable dermatologic clinicians to order Castle’s De
- European Medicines Agency Set to Review Incyte’s Ruxolitinib Cream in Vitiligohttps://practicaldermatology.com/news/european-medicines-agency-set-to-review-incytes-ruxolitinib-cream-in-vitiligo/2460970/The European Medicines Agency validated the European Marketing Authorization for Incyte’s ruxolitinib cream as a potential treatment for adolescents and adults (age >12 years) with non-segmental vitiligo with facial involvement. The validation of the Marketing Author